Lilly/Incyte announce peer-reviewed publication of Baricitinib/remdesivir trial data

 

• Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announce that the New England Journal of Medicine has published peer-reviewed results of the Phase 3 trial for baricitinib with remdesivir in hospitalized patients with COVID-19. The results support the emergency use authorization issued for the therapy by the FDA last month for adults and pediatric patients requiring supplemental oxygen.
• The ACTT-2 study was a double-blind, placebo-controlled trial sponsored by the National Institute of Allergy and Infectious Diseases.
• Andre Kalil, M.D., a principal investigator of the ACTT studies and the lead study author of the ACTT-2 New England Journal of Medicine manuscript, says "Results of this study demonstrated baricitinib in combination with remdesivir provided a faster median recovery time and reduced progression to ventilation or death compared to remdesivir alone in hospitalized COVID-19 patients on oxygen."
• Baricitinib, discovered by Incyte and licensed to Lilly, is an oral JAK inhibitor, approved for adults with moderate to severe rheumatoid arthritis in the U.S., and for moderate to severe atopic dermatitis, in the EU.
• https://seekingalpha.com/news/3643811-eli-lilly-incyte-announce-peer-reviewed-publication-of-baricitinib-remdesivir-trial-data